Latest news & press releases prev  -  next

FLT3 programme licensing opportunity

Sentinel Oncology is pleased to announce that its FLT3 kinase programme is available for partnering.

Mutations in the FLT3 gene are amongst the most frequent genetic defects found in acute myeloid leukemia (AML). Sentinel Oncology has developed a novel lead series of small molecule drugs which act as potent inhibitors of FLT3 and represent an excellent opportunity to develop pre-clinical candidate drugs... read more

For more information about the Sentinel Oncology p70S6 kinase programme, visit our website at www.sentineloncology.com or contact us to arrange a collaborative discussion.

March 30, 2010